Last reviewed: November 2017
Last updated: November  2017

Summary

Definition

History and exam

Key diagnostic factors

  • hx of Helicobacter pylori gastritis
  • hx of autoimmune disorder
  • age >60 years
  • dyspepsia
  • epigastric discomfort
  • skin lesions
  • red eye ± photophobia
  • painless proptosis, diplopia, motility disturbances of the eye, ptosis, decreased vision

Other diagnostic factors

  • nausea and/or vomiting
  • GI bleeding
  • fever
  • night sweats
  • weight loss
  • shortness of breath, haemoptysis, cough
  • salivary gland swelling
  • thyroid swelling
  • breast lump
  • focal neurological deficits
  • lymphadenopathy

Risk factors

  • Helicobacter pylori infection
  • age >60 years
  • autoimmune diseases
  • female sex
  • Chlamydia psittaci infection
  • Campylobacter jejuni infection
  • Borrelia burgdorferi infection
  • hepatitis C virus infection
  • HIV infection

Diagnostic investigations

1st investigations to order

  • FBC
  • blood smear
  • upper GI endoscopy
  • biopsy of affected tissue
  • H pylori serology
  • H pylori stool antigen test
  • LFTs
  • basic metabolic profile
Full details

Investigations to consider

  • bone marrow biopsy
  • immunohistochemistry
  • reverse transcriptase polymerase chain reaction (RT-PCR) or fluorescence in situ hybridisation (FISH)
  • immunoglobulin gene rearrangement studies
  • serum electrophoresis
  • serum LDH
  • serum beta-2 microglobulin
  • staging CT scan
  • endoscopic ultrasound of the stomach
  • double contrast radiography of the GI tract
  • lower GI endoscopy
  • endoscopic otolaryngology
  • CT scan of salivary glands
  • MRI orbit
  • hepatitis C serology
  • hepatitis B serology
  • HIV serology
  • multiple-gated acquisition scan (MUGA)
  • echocardiography
  • ethylenediamine tetra-acetic acid glomerular filtration rate (EDTA GFR)
Full details

Treatment algorithm

Contributors

Authors VIEW ALL

Consultant Haematologist

Luton and Dunstable Hospital NHS Foundation Trust

Luton

UK

Disclosures

RJ declares that he has no competing interests.

Consultant Haematologist

Royal Free Hospital

London

UK

Disclosures

CM declares that he has no competing interests.

Peer reviewers VIEW ALL

Professor of Medicine

Department of Internal Medicine I

Division of Oncology

Medical University Vienna

Austria

Disclosures

MR is an author of a number of references cited in this monograph.

Staff Hematologist

Cleveland Clinic Taussig Cancer Center

Cleveland

OH

Disclosures

AL declares that he has no competing interests.

Consultant Medical Oncologist

Royal Marsden Hospital

Sutton

UK

Disclosures

IC has been reimbursed by Roche Products, the manufacturer of rituximab, for attending several conferences. IC has also served on advisory boards and received honorarium for giving presentations for Roche Products. IC has received research funding from Novartis to conduct academic studies in the treatment of colorectal cancer.

Use of this content is subject to our disclaimer